In a 3-year extension of the pivotal trials that provided lebrikizumab with an indication for atopic dermatitis, the response ...

Eli Lilly's Ebglyss gains FDA approval for atopic dermatitis treatment, poised to rival Dupixent with strong performance in ...

Atopic Dermatitis, commonly called Eczema, affects millions globally with cases rising in India. Misunderstandings about its ...

Discover research presented at EADV 2024 highlighting the significant impact of atopic dermatitis on psychological and social ...

Topline results were announced from a phase 3 trial evaluating rocatinlimab for the treatment of moderate to severe atopic dermatitis.

Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...

Galderma today announced that it will present new data from the ARCADIA and OLYMPIA clinical trial programs investigating ...

The U.S. Food and Drug Administration has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 ...

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of the international CorEvitas Adolescent Atopic Dermatitis (AD) Registry, designed to study novel ...

AbbVie has revealed positive data from a post-hoc analysis of Phase III trials of RINVOQ in treating atopic dermatitis (AD).

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

(RTTNews) - Arcutis Biotherapeutics Inc.'s (ARQT) ZORYVE cream 0.15% provided consistent and meaningful improvements in signs and symptoms of atopic dermatitis in individuals regardless of race, ...